Welcome to the What’s New section of the National Fibromyalgia Research Association’s website. In this section we’ll highlight new treatments, including medications that show promise in helping to alleviate fibromyalgia symptoms. Or, we may highlight just beginning research studies and the researchers involved.
You will also find news regarding fibromyalgia advocacy, special conferences and events, new publications and news from patient organizations. On occasion, we will highlight researchers and other medical professionals we feel others should hear about. Check back often. Whether you are a medical professional, researcher, patient or family member, we’ll be highlighting something that will interest you!
Click here for the most recent posting to What
’s New. For a review of previous topics, click on the date of the item in the What’s New Archive.
What’s New Archive
Obesity Link to Fibromyalgia
A study by the University of Utah evaluated the relationship between fibromyalgia and obesity. They hypothesized that obesity significantly adds to the disease and disability burden of the condition.
New Diagnostic Criteria
The American College of Rheumatology (ACR) is proposing a new set of diagnostic criteria for fibromyalgia that includes common symptoms such as fatigue, sleep disturbances, and cognitive problems, as well as pain.
Fibromyalgia Wellness Project
The Fibromyalgia Wellness Research Project has been launched by Collinge and associates, an independent research organization directed by William Collinge, PhD
FDA approves Savella
The US Food and Drug Administration (FDA) has approved Savella (Milnacipran HCl) for the management of fibromyalgia.
The National Fibromyalgia Research Association highlights two opportunities for medical professional education.
NFRA's conference, Fibromyalgia and Sleep Disorders and the Massachusetts General Hospital's program, New Perspectives on Fibromyalgia and Related Illnesses
FDA approves Cymbalta
The US Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) for the management of fibromyalgia.
Showing he cares
Calvin Preston's college research paper on fibromyalgia is a labor of love for his wife.
Society for Women’s Health Research hosts online discussion on fibromyalgia...
The Society for Women's Health Research will host an online discussion of fibromyalgia syndrome with Patrick B. Wood, MD.
Milnacipran presented to the FDA...
Forest Laboratories, Inc. and Cypress Bioscience, Inc. jointly announced on New Year's Eve submission of New Drug Application to the FDA for milnacipran for the treatment of fibromyalgia.
The year in review...
Many new beginnings for NFRA this year. Read more about what happened in 2007.
FDA Approved Medication . . .
Pfizer's Lyrica receives FDA approval for the indication of fibromyalgia.
Medical Education Grant . . .
Eli Lilly and Company has awarded NFRA $46,500 to support the Fibromyalgia Assembly sponsored by NFRA at PAINWeek 2007.
Two NEW articles . . .
We’d like you to know about – the results of the treatment of cervical myelopathy in patients also diagnosed with fibromyalgia and the first published randomized, double-blind, placebo-controlled research study of gabapentin in fibromyalgia.
Emma Z's Letter
Emma Z. has found a way to show her love for her mom who has fibromyalgia and support fibromyalgia research. Maybe you can find your own way to make a difference!
The Year in Review
The National Fibromyalgia Research Association staff was busy in 2006.
Read about what we accomplished to accomplish our mission of education, treatment and finding a cure for fibromyalgia.
September 2006 – The Fibromyalgia and Central Nervous System Symposium
Our fifth researcher’s symposium, Fibromyalgia and the Central Nervous System Symposium was held in Salem, Oregon in September 2006. Seventeen researchers made presentations over the two days that were facilitated by Dr. Robert Bennett. DVDs of the presentations are available through our shopping cart.
June 2006 – Andrew Holman, MD, rheumatologist, Renton, Washington
Our first What’s New item highlights Dr. Andrew Holman and his work with dopamine agonists. His recently published article regarding positive research results for the treatment of fibromyalgia using Pramipexole made national news. Included is the abstract of this study.